Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Author: AndersonMatt S, ButtertonJoan R, De LepeleireInge, GilmartinJocelyn, GuoYing, LiuRachael, RobberechtsMartine, SchürmannDirk, SobothaChristian, WagnerFrank, WagnerJohn A, YeeKa Lai

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Doravirine monotherapy demonstrated robust antiviral activity without evidence of viral resistance and was generally well tolerated in HIV-infected men.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the antiviral activity, pharmacokinetics, and safety of doravirine in nonnucleoside reverse transcriptase inhibitor-naïve, HIV-infected men. DESIGN: Double-blind, randomized, two-panel, dose-escalation study. METHODS: In two sequential panels, 18 individuals received doravirin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0000000000000876

データ提供：米国国立医学図書館（NLM）

Doravirine: A Promising New Antiretroviral Agent for Treatment-Naïve HIV Individuals

Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that shows promise as a treatment for HIV infection. This research assesses the antiviral activity, pharmacokinetics, and safety of doravirine in treatment-naïve HIV-infected individuals.

A New Oasis in the Desert of HIV Treatment

The study involved a double-blind, randomized, two-panel, dose-escalation trial. Participants received doravirine (25 mg or 200 mg) or placebo once daily for 7 days. The results indicated that doravirine monotherapy demonstrated robust antiviral activity at both dose levels without evidence of viral resistance. Doravirine pharmacokinetics in HIV-infected individuals were similar to those in uninfected individuals receiving similar doses in prior studies. Adverse events were limited, transient, and generally mild to moderate in intensity.

Navigating the Desert of HIV Treatment: A New Path Forward

The discovery of new and effective antiretroviral drugs is essential for improving the lives of individuals living with HIV. Doravirine holds promise as a safe and effective treatment option, offering a new path through the desert of HIV infection.

Dr. Camel's Conclusion

The development of new antiretroviral agents is a beacon of hope in the desert of HIV treatment. Doravirine demonstrates the potential for a new and effective weapon against this challenging virus. Like a camel seeking a safe passage across the desert, we must continue our quest for new therapies to improve the lives of those affected by HIV.
Date :
  1. Date Completed 2016-11-14
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

26372481

DOI: Digital Object Identifier

10.1097/QAD.0000000000000876

Related Literature

Article Analysis
・Side Effects of doravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.